medicina58巻1号

2021年01月発行

特集 エキスパートに学ぶ—最新の循環器治療薬の使い方 循環器common diseaseの治療を再考する

高血圧

著者： 佐藤宏行¹

所属機関： ¹手稲渓仁会病院循環器内科

ページ範囲：P.134 - P.139

Question 1
ガイドラインの目標値には根拠がありますか？使用する薬剤により予後は影響されますか？

参考文献

1）日本高血圧学会高血圧治療ガイドライン作成委員会（編）：高血圧診療ガイドライン2019．日本高血圧学会，2019

2）Lewington S, et al：Age-specific relevance of usual blood pressures to vascular mortality；A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360：1903-1913, 2002

3）NIPPON DATA80 Research Group：Risk assessment chart for death from cardiovascular disease based on a 19-year follow-up study of a Japanese representative population. Circ J 70：1249-1255, 2006

4）Fujiyoshi A, et al：Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res 30：947-953, 2012

5）SPRINT Research Group：A randomized trial of intensive versus standard blood-pressure control. N Engl J Med 373：2103-2116, 2015

6）Helgeland A：Treatment of mild hypertension；A five year controlled drug trial. The Oslo study. Am J Med 69：725-732, 1980

7）JATOS Study Group：Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients（JATOS）. Hypertens Res 31：2115-2127, 2008

8）Ogihara T, et al：Target blood pressure for treatment of isolated systolic hypertension in the elderly；Valsartan in elderly isolated systolic hypertension study. Hypertension 56：196-202, 2010

9）ACCORD Study Group：Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362：1575-1585, 2010

10）Lv J, et al：Effects of intensive blood pressure lowering on the progression of chronic kidney disease；A systemic review and meta-analysis. CMAJ 185：949-957, 2013

11）Denardo SJ, et al：Coronary revascularization strategy and outcomes according to blood pressure（from the International Verapamil SR-Trandolapril Study［INVEST］）. Am J Cardiol 106：498-503, 2010

12）Arima H, et al：Lower target blood pressure are safe and effective for the prevention of recurrent stroke；The PROGRESS trial. J Hypertens 24：1201-1208, 2006

13）厚生科学審議会地域保険健康増進栄養部会．時期国民健康づくり運動プラン策定専門委員会：健康日本21（第2次）の推進に関する参考資料．厚生労働省．2012

14）Cheng Y, et al：Renoprotective effects of renin-angiotensin system inhibitor combined with calcium blocker or diuretic in hypertensive patients；A PRISMA-compliant meta-analysis. Medicine（Baltimore）95：e4167, 2016

15）Matsuzaki M, et al：Prevention of cardiovascular events with calcium channel blocker-based combination therapies in patients with hypertension；A randomized controlled trial. J Hypertens 29：1649-1659, 2011

16）Oikawa T, et al：J-HOME Study Group：Characteristics of resistant hypertension determined by self-measured blood pressure at home and office blood pressure measurements；The J-HOME study. J Hypertens 24：1737-1743, 2006

17）Nishizaki MK, et al：Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16：925-930, 2003